Letters to the Editor

In reply to Vergier *et al*: Fluorescence *in situ* hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases

Modern Pathology (2012) **25**, 1176; doi:10.1038/modpathol.2011.187

To the Editor: The study by Vergier *et al*¹ on the impact of FISH as a diagnostic aid in ambiguous melanocytic tumors contains logical and factual errors. By comparison with outcome they found that the sensitivity and specificity of histopathological review were 95 and 52%, and the sensitivity and specificity of FISH were 43 and 80%. They also state that ‘by considering cases as truly malignant only if histopathological diagnosis was ‘favor malignant’ and FISH positive, the diagnosis was optimized, especially by increasing specificity (76% instead of 52% for expert diagnosis alone), and also by improving sensitivity compared with FISH alone (90 vs 43% for FISH result alone)’. However, it is impossible to increase both the sensitivity and the specificity by combining two binary tests. From their Table 2 one can deduce that if truly malignant is defined as double positives (ie, histopathological review favors malignant and FISH is positive) the sensitivity would be 43% (9 out of 21) and not 90% as stated by the authors. Sequential testing as proposed by the authors shifts the threshold in favor of either sensitivity or specificity but not in favor of both, ie, it does not improve the diagnostic accuracy. Thus, their statement that ‘the histopathological diagnosis combined with FISH data improves the accuracy of diagnosis’ is factually wrong.

In the light of the fact that of 21 cases with metastases 20 were favored malignant by histopathological review and only 9 of these were positive by FISH the statement that ‘the value of FISH test is to add a reproducible demonstration of malignancy to the histopathological diagnosis, especially in doubtful/ambiguous melanocytic tumors’, is also factually wrong.

Disclosure/conflict of interest

The author declares no conflict of interest.

Harald Kittler

Department of Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria

E-mail: harald.kittler@meduniwien.ac.at

Reference

- 1 Vergier B, Prochazkova-Carlotti M, de la Fouchardiere A, *et al*. Fluorescence *in situ* hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. *Mod Pathol* 2011;24:613–623.

Response to Harald Kittler

Modern Pathology (2012) **25**, 1176–1177; doi:10.1038/modpathol.2012.86

To the Editor: As Harald Kittler stated,¹ it is impossible to increase both the sensitivity and the specificity of a diagnosis strategy based on two binary tests by combining them, in comparison to considering them alone. In our study² combining the results of a histopathological review and a FISH test for the diagnosis of ambiguous melanocytic tumors, we considered a case as positive if both histopathological review and FISH were positive, and a case as negative if both histopathological review and FISH test were

negative, omitting to consider as negative also the cases that were negative for one of the two tests.

Therefore we recalculated the test performance (Table 1) from the initial individual results (Table 2). Our conclusion is still that the specificity of the combined tests was increased (89%), compared with histopathological review alone (52%) and FISH test alone (80%). The positive predictive value of the combined tests tended to be increased (57%), compared with FISH alone (39%) and

Table 1 Comparison of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV)

	<i>FISH compared with outcome (%)</i>	<i>Histopathological review/outcome (%)</i>	<i>Combination of the two positive tests (%)</i>
Sensitivity	43	95	57
Specificity	80	52	89
PPV	39	41	57
NPV	82	97	89

Table 2 Combination of histopathological review and FISH test

	<i>Adverse event</i>	<i>Recurrence-free follow-up</i>
A+ ^a and FISH + ^b	12 Patients	9 Patients
A– and FISH–	1 Patient	28 Patients
<i>The others cases</i> (A+/FISH– or A–/FISH+)	8 Patients	42 Patients

^aExpert final histopathological diagnosis: favor malignant (A+); favor benign (A–).

^bFISH result: positive (+), negative (–).

histopathological review alone (41%). This latter result is, however, flawed owing to a selection bias: the group of patients with metastases was enriched

by the selection of patients with metastases whatever the follow-up time, whereas patients were considered as recurrence-free with at least a 5-year follow-up time. The take-home message is that FISH combined with histopathological review could be helpful in ambiguous melanocytic tumors for rejecting the diagnosis in a patient without adverse event (metastasis) at the expense of increasing the proportion of false-positive cases.

Disclosure/conflict of interest

The author declares no conflict of interest.

Béatrice Vergier

*Service de Pathologie, EA 2406, CHU
Bordeaux - Université Victor Segalen Bordeaux 2,
Hopital Haut-Lévêque, Bordeaux, France
E-mail: beatrice.vergier@chu-bordeaux.fr*

References

- 1 Kittler H. In reply to Vergier *et al*: Fluorescence *in situ* hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. *Mod Pathol* 2012;25:1176 (this issue).
- 2 Vergier B, Prochazkova-Carlotti M, de la Fouchardière A, *et al*. Fluorescence *in situ* hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. *Modern Pathol* 2011;24:613–623.